Intellia Therapeutics Inc

This non-binding advisory proposal asks stockholders to approve, on an advisory basis, the overall compensation of Intellia’s named executive officers as disclosed in the proxy statement, encompassing the Compensation Discussion and Analysis, the Summary Compensation Table, and related narrative disclosures. Management seeks approval to validate its pay-for-performance framework, which combines base salary, annual cash incentives tied to corporate and individual goals, and long-term equity awards (options, time-based RSUs, and market-based PSUs) intended to align management and stockholder interests. The board emphasizes that the vote is advisory and non-binding but will be considered by the compensation committee when setting future compensation; the company highlights prior engagement with stockholders and a 71.1% affirmative vote in 2025 as supportive context. The compensation program is positioned as calibrated for retention and to incentivize execution of clinical and commercial milestones—particularly given Intellia’s Phase 3 programs and planned commercial activities—and includes features such as stock ownership guidelines, clawback policy, and a mix of performance-based equity to mitigate undue risk-taking. Management also details governance safeguards (independent compensation committee, consultant engagement, benchmarking to peers, caps, and the use of double-trigger change-in-control arrangements) to justify the proposal. Potential considerations for sophisticated investors include the non-binding nature of the vote, the company’s demonstrated stockholder outreach, the presence of market-based PSUs that tie pay to relative TSR, and the fact that broker non-votes do not count in the outcome. The compensation committee’s rationale centers on aligning long-term stockholder value creation with executive incentives while retaining key talent during critical clinical and commercialization inflection points. Investors should weigh the disclosed compensation mix and governance protections against dilution, burn rate, and the company’s clinical and regulatory risks when evaluating the advisory proposal.

This agenda item is a procedural catch-all that reserves consideration for any other business that may properly come before the Annual Meeting, including proposals or matters not specifically disclosed in the proxy materials. It authorizes the named proxies and company representatives to exercise discretionary voting power on unforeseen items, subject to applicable law and the instructions (if any) provided by stockholders; the board states it is unaware of any additional matters as of the filing date. For investors, this item presents no substantive policy change but is important governance-wise because it confirms proxies will use their judgment if new items arise during the meeting. The company’s practice and disclosure make clear that there is no board recommendation tied to this item and that, historically, such items seldom contain material proposals. In the event a new proposal is presented from a stockholder at the meeting, the voting outcome may depend on whether broker nominees can exercise discretion and whether the matter is considered properly presented under the company’s bylaws. The board’s rationale for including this item is to enable orderly conduct of the meeting and ensure that any procedural or emergent matters may be addressed without additional proxy solicitation. From a risk perspective, this item is neutral, but active investors seeking to introduce substantive business should follow the company’s advance notice and SEC Rule 14a-8 procedures to ensure consideration in future proxy cycles. The absence of any substantive text in the proxy confirms management does not anticipate material additional business, and the board will exercise its delegated discretion in line with stockholder interests and fiduciary duties.